Program Resources
Review Papers
-
Initial injectable therapy in type 2 diabetes: key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin
-
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility
-
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
Study Publications
-
BEYOND: Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
-
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
-
CREDENCE: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
-
DAPA-CKD: Dapagliflozin in Patients with Chronic Kidney Disease
-
DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
-
ELEMENT-2: Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial.
Study Publications
-
EMPA-KIDNEY (Rationale): The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
-
EMPEROR-Preserved: Empagliflozin in Heart Failure with a Preserved Ejection Fraction
-
EMPEROR-Reduced: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
-
SoliMix: Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
-
SORELLA 2: Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine
-
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Guidelines
-
Diabetes Canada Pharmacologic Management: 2020 Update
-
Diabetes Canada Pharmacologic Management: 2020 Update – User’s Guide
-
2020 Clinical Practice Guidelines - Quick Reference Guide
-
2018 Diabetes Canada Guidelines, Chapter 14: Hypoglycemia
-
2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
-
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
